Currently Viewing:
Currently Reading
What We're Reading: Humana to Quit Exchanges; Polypharmacy in the Elderly; and FDA Shake-ups
February 15, 2017 – AJMC Staff
Medicaid Expansion Could Have Reduced Medical Divorce, Not Just Uninsurance
February 14, 2017 – Christina Mattina
FDA Issues Alert About Fluid-Filled Balloons to Treat Obesity
February 14, 2017 – AJMC Staff
What We're Reading: Shulkin Confirmed; Privatizing Medicaid Transportation; and GOP on Healthcare
February 14, 2017 – AJMC Staff
Aetna, Humana Call Off $37 Billion Merger; Cigna Sues Anthem for $13 Billion
February 14, 2017 – Mary Caffrey
Navigator Program Lowered Costs, Utilization for Elderly Cancer Patients
February 13, 2017 – Christina Mattina
What We're Reading: DMD Drug Gets $89K Price Tag; Necessary Drug Price Hikes; and ACA Taxes
February 13, 2017 – AJMC Staff
Tom Price Is Confirmed as HHS Secretary, Will Lead ACA Repeal
February 10, 2017 – Laura Joszt
This Week in Managed Care: February 10, 2017
February 10, 2017

What We're Reading: Humana to Quit Exchanges; Polypharmacy in the Elderly; and FDA Shake-ups

AJMC Staff

Humana to Pull Out of 2018 Exchanges

Shortly after calling off its proposed merger with Aetna, Humana announced it would not participate in the Affordable Care Act exchanges in 2018. After analyzing membership data from the 2017 open enrollment period, “Humana is seeing further signs of an unbalanced risk pool,” the insurer stated in a press release explaining the decision. In a tweet, President Donald Trump seized the news as an example of how “Obamacare continues to fail.”

Polypharmacy On the Rise in Elderly Patients

A study recently published in JAMA Internal Medicine points to a concerning trend of physicians prescribing 3 or more central nervous system (CNS) drugs at once for elderly patients. CNS polypharmacy among those aged 65 or older has more than doubled between 2004 and 2013, partially driven by an increase in prescribing among patients with a pain diagnosis. The largest increase in CNS polypharmacy was among rural visits, “where access to specialty mental health or pain care is particularly limited,” the authors wrote.

Pharma Executives Keep Wary Eye on FDA's Future

President Trump’s calls to slash government regulations and speed up the FDA’s drug approval processes have put some pharmaceutical industry leaders on edge, according to a Reuters article. Over a dozen drug and biotechnology firms have implored the new administration not to implement a too-hasty approval process, worrying that insurers will refuse to pay for a new drug if its safety is not thoroughly proven. "It is one thing to get a drug approved, but you have got to get reimbursed," said Paul Perreault, chief executive of biotech company CSL Ltd, in the article.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up